Materials on the basis of cycloolefin copolymers (COC) are suitable for subchondral defect repairs. The objective of this study was to evaluate the influence of surface modification of COC and COC/LLDPE blends on the viability and gene expression of chondrocytes. Human chondrocytes were incubated on the surface of the studied materials. Half of the materials were plasmatically modified with a subsequent type II collagen application. The gene expression of matrix metalloproteinases (MMP-1,-3,-13), pro-inflammatory cytokines (IL-1, TNF-alpha) and apoptotic molecules (BAX, Bcl-2) was evaluated using quantitative Taq-Man PCR after 48 h incubation. Chondrocyte viability was evaluated by the MTT test after 2, 4 and 8 days of incubation. The synthesis of MMPs was measured by ELISA assay in cell culture medium after 48 h of incubation. Chondrocytes incubated on plasmatically modified in contrast to unmodified materials demonstrated significantly increased gene expression of IL-1 (p<0.05), MMP-1 and MMP-3 (p<0.05 for both comparisons) as well as MMP-13 (p<0.001). Increased gene expression was confirmed by significantly increased production of active forms of particular MMPs into the cell culture medium. Unlike surface unmodified polymers, the modified materials showed timedependent reduction of chondrocyte viability. The gene expression of TNF-? and apoptotic molecules by chondrocytes was not significantly changed by different materials. Cycloolefin copolymers and their blends may represent suitable materials for tissue engineering, however, their surface modification followed by collagen type II application may, at least under in vitro conditions, reduce the viability of chondrocytes and induce their pro-destructive behavior. The potential benefit or disadvantage of surface modifications of materials for osteochondral defect repairs needs to be further elucidated.

• MeSH
• Apoptosis drug effects   MeSH
• Biocompatible Materials pharmacology   MeSH
• Cell Line MeSH
• Chondrocytes cytology   physiology   drug effects   MeSH
• Cycloparaffins pharmacology   MeSH
• Gene Expression drug effects   MeSH
• Financing, Organized MeSH
• Interleukin-1 genetics   MeSH
• Collagen Type II pharmacology   MeSH
• Humans MeSH
• Matrix Metalloproteinase 1 genetics   metabolism   MeSH
• Matrix Metalloproteinase 13 genetics   metabolism   MeSH
• Matrix Metalloproteinase 3 genetics   metabolism   MeSH
• Osteoarthritis drug therapy   pathology   MeSH
• Polymers pharmacology   MeSH
• Prostheses and Implants MeSH
• Materials Testing MeSH
• Tumor Necrosis Factor-alpha genetics   MeSH
• Cell Survival drug effects   MeSH
• Check Tag
• Humans MeSH